Glucose-6-phosphate dehydrogenase and transketolase: Key factors in breast cancer progression and therapy
View abstract on PubMed
Summary
This summary is machine-generated.The pentose phosphate pathway (PPP) fuels breast cancer growth and resistance. Targeting key enzymes like G6PD and TKT in the PPP offers new therapeutic strategies for breast cancer treatment.
Area Of Science
- Oncology
- Biochemistry
- Molecular Biology
Background
- Breast cancer is a leading cause of mortality in women.
- The pentose phosphate pathway (PPP) is crucial for cellular metabolism and survival.
- Aberrant PPP activation promotes breast cancer progression and chemoresistance.
Purpose Of The Study
- To elucidate the role of the PPP in breast cancer malignancy.
- To detail the mechanisms of key PPP enzymes, Glucose-6-phosphate dehydrogenase (G6PD) and Transketolase (TKT), in cancer progression.
- To explore potential therapeutic strategies targeting the PPP in breast cancer.
Main Methods
- Review of existing literature on PPP and breast cancer.
- Analysis of the biochemical functions of G6PD and TKT.
- Discussion of the implications of PPP dysregulation in cancer.
Main Results
- G6PD produces NADPH, supporting lipid synthesis and ROS resistance.
- TKT generates R5P, essential for DNA/RNA synthesis and repair.
- PPP hyperactivity drives proliferation, invasion, and drug resistance in breast cancer.
Conclusions
- The PPP is a critical metabolic pathway supporting breast cancer's malignant phenotype.
- Targeting G6PD and TKT presents a promising avenue for novel breast cancer therapies.
- Understanding PPP mechanisms provides a basis for future breast cancer research and treatment.
Related Concept Videos
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
In cellular metabolism (the complete breakdown of glucose to extract energy), glycolysis is the first step. Glycolysis takes place in the cytoplasm of both prokaryotic and eukaryotic cells. Glucose enters heterotrophic cells in two ways. One method is through secondary active transport, where the transport takes place against the glucose concentration gradient. The other mechanism uses a group of integral proteins called GLUT proteins, also known as glucose transporter proteins. These...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

